Romesh Vaitilingam, 22 May 2021

There is much debate about whether the patents on Covid-19 vaccines should be waived to allow low-income countries to produce doses for themselves. The IGM Forum at Chicago Booth invited its panels of leading European and US economists to express their views on this issue and the broader challenges of vaccinating the world. As this column reports, a strong majority (87% of the panellists) agrees that rather than waiving intellectual property protection, the rich countries should pay the pharmaceutical companies to manufacture and distribute the vaccines (or to license production and support licensees). A similarly strong majority (89%) considers that the benefits to the rich countries of paying for 12 billion doses and providing them to the rest of the world exceed the costs.


CEPR Policy Research